STING1 and breast carcinoma: In a HER2+ breast cancer mouse model, adding a STING agonist to a novel peptide vaccine targeting heat shock protein 90 fostered T-cell rearrangement of TCRβ, prolonging mouse survival.575 Furthermore, a vaccine consisting of STING agonist 2’3’-cGAMP, TLR9 ligand CpG, and tumor antigen peptides loaded into nanoporous microparticles effectively inhibited tumor growth.